Beijing Increasepharm Corporation Limited (Increasepharm)

Founded in 1999, lead in Traditional Chinese Medicine R&D, focusing on independent R&D, supplemented by CRO, and is a high-tech enterprise with full chain system and special in new formulation development. Increasepharm has become the only TCM R&D enterprise that can be listed in stock market due to three strong points of differentiation: 1 TCM new drug development base on clinical using, 2 TCM New formulation development, 3 IND or NDA through screening on TCM.

The headquarter is located in Zhongke Yungu Park, Changping District, Beijing. As it develops, Increasepharm has many honors and qualifications granted by governments, such as National High-tech Enterprises, Post-doctoral Workstations, Beijing Enterprise Technology Center, Tianjin Key Laboratory of Pulmonary Administration and Guangdong Nebulization Inhalation Engineering Technology Center and get CNAS certification for Chemical medicine and TCM, in 2019 won first prize of Beijing Science and Technology Progress. At the same time, special committees of 6 national societies like China Association of TCM, World Federation of TCM conduct academic research in our company, which support the inheritance, innovation and development of pharmaceutical industry.

Increasepharm has established 13subsidiaries in Beijing, Tianjin, Zhuhai, Shanghai and Hong Kong. The company has five major business areas, including TCM, New Drug, New Formulation,Clinical Service, Manufacturing and International Business; it has set 18 R&D platforms, covering project initiation, R&D, Transformation and Industrialization, can conduct Start to End development.

Facilities including R&D area 40,000 m2, production base 60 Mu, precision instruments or equipment 1,000 sets,

Staff: more than 700 R&D personnel, more than 50% won master degree or senior titles or above,80 are senior Ph.D or senior title or national expert.  

Honor: Total 138, including 47 national,81 provincial and municipal ,and 10 district.

Won the national 863 project, 15 major new drug innovation projects listed in "Eleventh Five-Year Plan", "Twelfth Five-Year Plan" and "Thirteenth Five-Year Plan" of Ministry of Science and Technology, and more than 20 other provincial and municipal projects.

Certificate: 12 New Drug License,29 Manufacturing License and 34 Clinical permission, total 75.

Patents: applied 555, authorized 145.

which proves our outstanding capability of innovation and R&D.

Increasepharm has partners and customers all over the world, providing professional service and core competitiveness products for pharmaceutical companies. They jointly undertake more than 1,000 projects including self R&D, technical transformation and technical services, and cumulative income adding up to RMB 2.1 billion.

Increasepharm sets mission of serving human health, responsibility of inheriting and promoting of TCM, adhering to the business philosophy of "Innovation-driven, Excellence-aimed, Integrity-based, Win-win cooperation", will continue to be committed to new drug R&D and insist on pursuing development through innovation and service. With the strong R&D strength, the company aims to provide new medicine and technical services with high-tech and good market prospects and uses independent innovation technology to promote the innovation of TCM, commit to building an excellent national brand and become a leading company in the field of TCM R&D.